デフォルト表紙
市場調査レポート
商品コード
1225476

網膜芽細胞腫治療市場:タイプ別(手術、放射線療法、レーザー療法、凍結療法、温熱療法、化学療法、眼動脈注入化学療法、高用量化学療法・幹細胞移植)、病期分類別、用途別、地域別、2023-2028年

Retinoblastoma Treatment Market by Type(Surgery, Radiation Therapy, Laser Therapy, Cryotherapy, Thermotherapy, Chemotherapy, Opthalmic Artery Infusion Chemotherapy, High-Dose Chemotherapy & Stem Cell Transplant, Staging) Application & Region 2023-2028

出版日: | 発行: IMARC | ページ情報: 英文 145 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
網膜芽細胞腫治療市場:タイプ別(手術、放射線療法、レーザー療法、凍結療法、温熱療法、化学療法、眼動脈注入化学療法、高用量化学療法・幹細胞移植)、病期分類別、用途別、地域別、2023-2028年
出版日: 2023年02月03日
発行: IMARC
ページ情報: 英文 145 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

市場概要

  • 世界の網膜芽細胞腫治療市場規模は、2022年に27億米ドルに達しました。今後、IMARCグループは、2023年から2028年の間に4.2%の成長率(CAGR)を示し、2028年までに35億米ドルに達すると予測しています。眼科治療に対する医療費の大幅な増加、副作用の少ない治療法の研究開発活動への投資の増加、健康意識の高まりなどが、市場を牽引する主な要因の1つとなっています。
  • 網膜芽細胞腫は、一般的に5歳未満の小児に発症する最も一般的ながんの1つです。網膜芽細胞腫の症状には、キャッツアイ反射や白斑と呼ばれる瞳孔の白濁があります。網膜芽細胞腫の治療には、様々なドラッグデリバリーや化学療法があり、網膜芽細胞腫は初期段階で治癒可能であるため、短期間で一定の効果が得られます。1回目または2回目の化学療法サイクルの後、腫瘍の縮小度合いと眼球内の位置に応じて、さまざまな局所治療を適用することができます。さまざまな治療法を組み合わせることが、網膜芽細胞腫の治療法として最も成功する方法です。手術は、網膜から腫瘍を完全に除去するため、恒久的な網膜芽細胞腫の治療法であると言えます。網膜芽細胞腫の詳細な診断には、超音波検査、CTスキャン、MRI、X線検査、骨スキャンなど、さまざまな画像検査があります。

網膜芽細胞腫の治療市場動向

  • 眼科治療処置のためのヘルスケア支出の大幅な増加は、市場を牽引する重要な要因です。これは、若年層における網膜芽細胞腫の発生率が上昇していることに起因しています。これに伴い、副作用の少ない、より効率的な治療法の研究開発への投資が増加していることも、市場を活性化させています。さらに、さまざまな種類のがんに対する認識が高まり、診断率や治療率が向上していることも、大きな成長促進要因となっています。しかし、様々な網膜芽細胞腫治療薬が入手できないことや、厳しい薬事規制が市場の成長抑制要因として作用しています。一方、新薬の上市につながる製品承認の数が増えていることは、市場に明るい展望を与えています。これに加えて、網膜芽細胞腫の再発率の増加も、網膜芽細胞腫治療市場に有利な機会を生み出しています。さらに、パートナーシップや提携、合併・買収(M&A)など、主要な支払者が実施するさまざまな有機的成長戦略が市場を後押ししています。これとは別に、強力なパイプライン医薬品の存在や、臨床試験数の増加が市場の成長を後押ししています。その他、急速な都市化、可処分所得水準の上昇、がん研究の大幅な増加、世界各地の医療インフラの改善なども、市場拡大の要因となっています。

主な市場セグメンテーション

  • IMARC Groupは、世界の網膜芽細胞腫治療市場の各セグメントにおける主要動向の分析と、2023年から2028年までの世界、地域、国レベルでの予測を提供します。当レポートでは、市場をタイプ、治療タイプ、病期分類タイプ、用途に基づき分類しています。

タイプのインサイト

  • 非血統性網膜芽細胞腫
  • 遺伝性網膜芽細胞腫
  • 当レポートでは、網膜芽細胞腫治療市場をタイプ別に詳細に区分・分析しています。これには、非遺伝性網膜芽細胞腫と遺伝性網膜芽細胞腫が含まれます。それ別と、非遺伝性網膜芽細胞腫が最大のセグメントを占めています。

治療タイプのインサイト

  • 外科手術
  • 放射線療法
  • レーザー治療(光凝固)
  • 凍結療法
  • 温熱療法
  • 化学療法
  • 眼動脈注入化学療法
  • 大量化学療法と幹細胞移植
  • 本レポートでは、治療タイプに基づく網膜芽細胞腫治療市場の詳細な区分と分析を行いました。これには、手術、放射線療法、レーザー療法(光凝固)、凍結療法、温熱療法、化学療法、眼動脈注入化学療法、大量化学療法および幹細胞移植が含まれます。それ別と、化学療法が最も大きなセグメントを占めています。

病期分類の洞察の種類

  • 眼内網膜芽細胞腫
  • 眼球外網膜芽細胞腫
  • 本レポートでは、網膜芽細胞腫治療市場を病期分類の種類に基づいて詳細に区分・分析しています。これには、眼内網膜芽細胞腫と眼外網膜芽細胞腫が含まれます。この報告書別と、眼内網膜芽細胞腫が最大のセグメントを占めています。

用途インサイト

  • 病院
  • がん研究機関
  • その他
  • また、用途に基づく網膜芽細胞腫治療市場の詳細な区分と分析も報告書に記載されています。これには、病院、がん研究機関、その他が含まれます。

地域別インサイト

  • 北米
  • 米国
  • カナダ
  • アジア太平洋地域
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
  • 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
  • ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
  • 中東およびアフリカ
  • また、北米(米国、カナダ)、アジア太平洋(中国、日本、インド、韓国、オーストラリア、インドネシア、その他)、欧州(ドイツ、フランス、英国、イタリア、スペイン、ロシア、その他)、南米(ブラジル、メキシコ、その他)、中東・アフリカを含むすべての主要地域市場について包括的に分析を行っています。それ別と、アジア太平洋地域は網膜芽細胞腫治療において最大の市場となっています。アジア太平洋地域の網膜芽細胞腫治療市場を牽引する要因としては、網膜芽細胞腫の再発率の上昇、さまざまな種類のがんに関する認知度の上昇による診断・治療率の上昇、同地域における複数の主要企業の存在などが挙げられます。

本レポートで回答した主な質問

  • 世界の網膜芽細胞腫治療市場はこれまでどのように推移し、今後数年間はどのように推移するのか?
  • 世界の網膜芽細胞腫治療市場における促進要因、市場抑制要因、機会とは?
  • 主要な地域市場は?
  • 最も魅力的な網膜芽細胞腫治療市場を代表する国はどこか?
  • タイプに基づく市場の内訳は?
  • 治療タイプに基づく市場の内訳は?
  • 病期分類に基づく市場の内訳は?
  • 用途に基づく市場内訳は?
  • 世界の網膜芽細胞腫治療市場の競争構造は?
  • 網膜芽細胞腫治療の世界市場における主要プレイヤー/企業は?

目次

第1章 序文

第2章 調査手法と範囲

  • 調査の目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 予測手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要な産業動向

第5章 世界の網膜芽細胞腫治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 タイプ別市場内訳

  • 非乾酪性網膜芽細胞腫
    • 市場動向
    • 市場予測
  • 遺伝性網膜芽細胞腫
    • 市場動向
    • 市場予測

第7章 治療タイプ別市場内訳

  • 手術
    • 市場動向
    • 市場予測
  • 放射線療法
    • 市場動向
    • 市場予測
  • レーザー療法(光凝固)
    • 市場動向
    • 市場展望
  • 凍結療法
    • 市場動向
    • 市場展望
  • 温熱療法
    • 市場動向
    • 市場予測
  • 化学療法
    • 市場動向
    • 市場予測
  • 眼動脈注入化学療法
    • 市場動向
    • 市場展望
  • 高用量化学療法・幹細胞移植
    • 市場動向
    • 市場予測

第8章 病期分類タイプ別市場内訳

  • 眼内網膜芽細胞腫
    • 市場動向
    • 市場予測
  • 外眼部網膜芽細胞腫
    • 市場動向
    • 市場展望

第9章 用途別市場内訳

  • 病院
    • 市場動向
    • 市場予測
  • がん研究機関
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第10章 地域別市場内訳

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場展望
  • アジア太平洋地域
    • 中国
      • 市場動向
      • 市場展望
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場展望
    • 韓国市場
      • 市場動向
      • 市場展望
    • オーストラリア
      • 市場動向
      • 市場展望
    • インドネシア
      • 市場動向
      • 市場展望
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場展望
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場展望
    • スペイン
      • 市場動向
      • 市場展望
    • ロシア
      • 市場動向
      • 市場展望
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場展望
    • メキシコ
      • 市場動向
      • 市場展望
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 国別市場内訳
    • 市場展望

第11章 促進要因、阻害要因、ビジネスチャンス

  • 概要
  • 促進要因
  • 抑制要因条件
  • ビジネスチャンス

第12章 バリューチェーン分析

第13章 ポーターズファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の度合い
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Bristol Myers Squibb Company
    • Pfizer Inc.
    • Teva Canada Limited(Teva Pharmaceutical Industries Ltd.)

本レポートに掲載されている企業名は一部であり、全企業名は本レポートに掲載されています。

図表

List of Figures

  • Figure 1: Global: Retinoblastoma Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Retinoblastoma Treatment Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Retinoblastoma Treatment Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Retinoblastoma Treatment Market: Breakup by Type (in %), 2022
  • Figure 5: Global: Retinoblastoma Treatment Market: Breakup by Treatment Type (in %), 2022
  • Figure 6: Global: Retinoblastoma Treatment Market: Breakup by Type of Staging (in %), 2022
  • Figure 7: Global: Retinoblastoma Treatment Market: Breakup by Application (in %), 2022
  • Figure 8: Global: Retinoblastoma Treatment Market: Breakup by Region (in %), 2022
  • Figure 9: Global: Retinoblastoma Treatment (Non-Hereditary Retinoblastoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Retinoblastoma Treatment (Non-Hereditary Retinoblastoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Retinoblastoma Treatment (Hereditary Retinoblastoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Retinoblastoma Treatment (Hereditary Retinoblastoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Retinoblastoma Treatment (Surgery) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Retinoblastoma Treatment (Surgery) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Retinoblastoma Treatment (Radiation Therapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Retinoblastoma Treatment (Radiation Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Retinoblastoma Treatment (Laser Therapy (Photocoagulation)) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Retinoblastoma Treatment (Laser Therapy (Photocoagulation)) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Retinoblastoma Treatment (Cryotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Retinoblastoma Treatment (Cryotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Retinoblastoma Treatment (Thermotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Retinoblastoma Treatment (Thermotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Retinoblastoma Treatment (Chemotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Retinoblastoma Treatment (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: Global: Retinoblastoma Treatment (Opthalmic Artery Infusion Chemotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: Global: Retinoblastoma Treatment (Opthalmic Artery Infusion Chemotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: Global: Retinoblastoma Treatment (High-Dose Chemotherapy and Stem Cell Transplant) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: Global: Retinoblastoma Treatment (High-Dose Chemotherapy and Stem Cell Transplant) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Global: Retinoblastoma Treatment (Intraocular Retinoblastoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Global: Retinoblastoma Treatment (Intraocular Retinoblastoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: Global: Retinoblastoma Treatment (Extraocular Retinoblastoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: Global: Retinoblastoma Treatment (Extraocular Retinoblastoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: Global: Retinoblastoma Treatment (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: Global: Retinoblastoma Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: Global: Retinoblastoma Treatment (Cancer Institutes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: Global: Retinoblastoma Treatment (Cancer Institutes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: Global: Retinoblastoma Treatment (Other Applications) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: Global: Retinoblastoma Treatment (Other Applications) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: North America: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: North America: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: United States: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: United States: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: Canada: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: Canada: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: Asia-Pacific: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: Asia-Pacific: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: China: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: China: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: Japan: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: Japan: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: India: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: India: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: South Korea: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: South Korea: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: Australia: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: Australia: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: Indonesia: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: Indonesia: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Others: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Others: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: Europe: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: Europe: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Germany: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Germany: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: France: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: France: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: United Kingdom: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: United Kingdom: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Italy: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Italy: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Spain: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: Spain: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Russia: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 74: Russia: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Others: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 76: Others: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Latin America: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 78: Latin America: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 79: Brazil: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 80: Brazil: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 81: Mexico: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 82: Mexico: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 83: Others: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 84: Others: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 85: Middle East and Africa: Retinoblastoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 86: Middle East and Africa: Retinoblastoma Treatment Market: Breakup by Country (in %), 2022
  • Figure 87: Middle East and Africa: Retinoblastoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 88: Global: Retinoblastoma Treatment Industry: Drivers, Restraints, and Opportunities
  • Figure 89: Global: Retinoblastoma Treatment Industry: Value Chain Analysis
  • Figure 90: Global: Retinoblastoma Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Retinoblastoma Treatment Market: Key Industry Highlights, 2022 & 2028
  • Table 2: Global: Retinoblastoma Treatment Market Forecast: Breakup by Type (in Million US$), 2023-2028
  • Table 3: Global: Retinoblastoma Treatment Market Forecast: Breakup by Treatment Type (in Million US$), 2023-2028
  • Table 4: Global: Retinoblastoma Treatment Market Forecast: Breakup by Type of Staging (in Million US$), 2023-2028
  • Table 5: Global: Retinoblastoma Treatment Market Forecast: Breakup by Application (in Million US$), 2023-2028
  • Table 6: Global: Retinoblastoma Treatment Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 7: Global: Retinoblastoma Treatment Market: Competitive Structure
  • Table 8: Global: Retinoblastoma Treatment Market: Key Players
目次
Product Code: SR1423A317_Report

Market Overview:

  • The global retinoblastoma treatment market size reached US$ 2.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 3.5 Billion by 2028, exhibiting a growth rate (CAGR) of 4.2% during 2023-2028. A considerable rise in healthcare expenditure for ophthalmic treatment procedures, increasing investments in research and development (R&D) activities on therapies with lower side effects, and the increasing health consciousness represent some of the key factors driving the market.
  • Retinoblastoma is one of the most common cancers that generally develops before the age of 5 in children. Some of the symptoms of retinoblastoma include a white appearance in the pupil called cat's eye reflex or leukocoria. Retinoblastoma treatment can include a variety of drug delivery and chemotherapy techniques that provide some benefits in the short term since retinoblastoma is curable at the initial stage. Following the first or second chemotherapy cycle, different focal treatments can then be applied depending on how much the tumor shrinks and where it is in the eye. A combination of different treatment methods is the most successful retinoblastoma treatment option. Surgery is the permanent retinoblastoma treatment option as it removes the tumor thoroughly from the retina. There are a variety of imaging tests available for a detailed diagnosis of retinoblastoma, including ultrasound, CT-scan, MRI, X-ray, and bone scan.

Retinoblastoma Treatment Market Trends:

  • A considerable rise in healthcare expenditure for ophthalmic treatment procedures is a significant factor driving the market. This can be attributed to the rising incidences of retinoblastoma among the younger population. In line with this, increasing investments in research and development (R&D) activities focusing on newer, more efficient therapeutic strategies with lesser associated side effects is providing an impetus to the market. Moreover, the growing awareness regarding different type of cancers resulting in higher diagnosis and treatment rates are also acting as a significant growth-inducing factor. However, the lack of availability of various retinoblastoma treatment drugs, along with stringent drug regulations, are acting as a growth-restraining factor for the market. On the contrary, the increasing number of product approvals leading to the launches of new drug variants is creating a positive outlook for the market. Besides this, the growing rates of recurrence of retinoblastoma are also creating lucrative opportunities in the retinoblastoma treatment market. The market is further propelled by various organic growth strategies undertaken by key payers, such as partnerships and collaborations, and merger and acquisitions (M&As). Apart from this, the presence of strong pipeline drugs, along with the augmenting number of clinical trials, are fueling the market growth. Some of the other factors contributing to the market include rapid urbanization, inflating disposable income levels, considerable growth in cancer research, and improvements in medical infrastructure across the globe.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each segment of the global retinoblastoma treatment market, along with forecasts at the global, regional, and country level from 2023-2028. Our report has categorized the market based on type, treatment type, type of staging, and application.

Type Insights:

  • Non-Hereditary Retinoblastoma
  • Hereditary Retinoblastoma
  • The report has provided a detailed breakup and analysis of the retinoblastoma treatment market based on the type. This includes non-hereditary retinoblastoma and hereditary retinoblastoma. According to the report, non-hereditary retinoblastoma represented the largest segment.

Treatment Type Insights:

  • Surgery
  • Radiation Therapy
  • Laser Therapy (Photocoagulation)
  • Cryotherapy
  • Thermotherapy
  • Chemotherapy
  • Opthalmic Artery Infusion Chemotherapy
  • High-Dose Chemotherapy and Stem Cell Transplant
  • The report has provided a detailed breakup and analysis of the retinoblastoma treatment market based on the treatment type. This includes surgery, radiation therapy, laser therapy (photocoagulation), cryotherapy, thermotherapy, chemotherapy, opthalmic artery infusion chemotherapy, and high-dose chemotherapy and stem cell transplant. According to the report, chemotherapy represented the largest segment.

Type of Staging Insights:

  • Intraocular Retinoblastoma
  • Extraocular Retinoblastoma
  • The report has provided a detailed breakup and analysis of the retinoblastoma treatment market based on the type of staging. This includes intraocular retinoblastoma and extraocular retinoblastoma. According to the report, intraocular retinoblastoma represented the largest segment.

Application Insights:

  • Hospitals
  • Cancer Institutes
  • Others
  • A detailed breakup and analysis of the retinoblastoma treatment market based on the application has also been provided in the report. This includes hospitals, cancer institutes, and others.

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific was the largest market for retinoblastoma treatment. Some of the factors driving the Asia Pacific retinoblastoma treatment market include the growing rates of recurrence of retinoblastoma, higher diagnosis and treatment rates due to the increasing awareness regarding different types of cancers, the presence of several key players in the region, etc.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global retinoblastoma treatment market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Bristol Myers Squibb Company, Pfizer Inc., Teva Canada Limited (Teva Pharmaceutical Industries Ltd.), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global retinoblastoma treatment market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global retinoblastoma treatment market?
  • What are the key regional markets?
  • Which countries represent the most attractive retinoblastoma treatment markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the type of staging?
  • What is the breakup of the market based on application?
  • What is the competitive structure of the global retinoblastoma treatment market?
  • Who are the key players/companies in the global retinoblastoma treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Retinoblastoma Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Non-Hereditary Retinoblastoma
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Hereditary Retinoblastoma
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Treatment Type

  • 7.1 Surgery
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Radiation Therapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Laser Therapy (Photocoagulation)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cryotherapy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Thermotherapy
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Chemotherapy
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Opthalmic Artery Infusion Chemotherapy
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast
  • 7.8 High-Dose Chemotherapy and Stem Cell Transplant
    • 7.8.1 Market Trends
    • 7.8.2 Market Forecast

8 Market Breakup by Type of Staging

  • 8.1 Intraocular Retinoblastoma
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Extraocular Retinoblastoma
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Cancer Institutes
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

  • 11.1 Overview
  • 11.2 Drivers
  • 11.3 Restraints
  • 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Bristol Myers Squibb Company
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Pfizer Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Teva Canada Limited (Teva Pharmaceutical Industries Ltd.)
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.